Johnson & Johnson
JNJ239.990USD
+2.200+0.93%
終値 02/06, 16:00（ET）15分遅れの株価
577.46B時価総額
21.75直近12ヶ月PER
詳細情報 Johnson & Johnson 企業名
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
Johnson & Johnsonの企業情報
企業コードJNJ
会社名Johnson & Johnson
上場日Oct 31, 2080
最高経営責任者「CEO」Duato (Joaquin Boix)
従業員数138100
証券種類Ordinary Share
決算期末Oct 31
本社所在地One Johnson & Johnson Plaza
都市NEW BRUNSWICK
証券取引所NASDAQ OMX NASDAQ Basic NYSE
国United States of America
郵便番号08933
電話番号17325242455
ウェブサイトhttps://www.jnj.com/
企業コードJNJ
上場日Oct 31, 2080
最高経営責任者「CEO」Duato (Joaquin Boix)
Johnson & Johnsonの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Joaquin Boix Duato
Mr. Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
276.91K
--
Ms. Jennifer L. Taubert
Ms. Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Executive Vice President, Worldwide Chairman, Innovative Medicine
178.01K
--
Ms. Kathryn E. Wengel
Ms. Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
Executive Vice President, Chief Technology Officer and Risk Officer
94.62K
+12015.00%
Mr. Joseph J. Wolk
Mr. Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
84.95K
--
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Executive Vice President - Global Corporate Affairs
Executive Vice President - Global Corporate Affairs
23.59K
+3760.00%
Ms. Elizabeth (Liz) Forminard
Ms. Elizabeth (Liz) Forminard
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
15.55K
+2695.00%
Ms. Kristen Mulholland
Ms. Kristen Mulholland
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
14.12K
+2430.00%
Prof. Dr. John C. Reed, M.D., Ph.D.
Prof. Dr. John C. Reed, M.D., Ph.D.
Executive Vice President - Innovative Medicine, Research and Development
Executive Vice President - Innovative Medicine, Research and Development
10.66K
--
Mr. Hubert Joly
Mr. Hubert Joly
Independent Director
Independent Director
5.00K
--
Ms. Marillyn A. Hewson
Ms. Marillyn A. Hewson
Lead Independent Director
Lead Independent Director
3.00K
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Joaquin Boix Duato
Mr. Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
276.91K
--
Ms. Jennifer L. Taubert
Ms. Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Executive Vice President, Worldwide Chairman, Innovative Medicine
178.01K
--
Ms. Kathryn E. Wengel
Ms. Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
Executive Vice President, Chief Technology Officer and Risk Officer
94.62K
+12015.00%
Mr. Joseph J. Wolk
Mr. Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
84.95K
--
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Executive Vice President - Global Corporate Affairs
Executive Vice President - Global Corporate Affairs
23.59K
+3760.00%
Ms. Elizabeth (Liz) Forminard
Ms. Elizabeth (Liz) Forminard
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
15.55K
+2695.00%
収益内訳
通貨: USD更新時刻: Tue, Jan 6
通貨: USD更新時刻: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
Oncology-DARZALEX
3.67B
15.30%
Immunology-STELARA
1.57B
6.54%
Immunology-TREMFYA
1.42B
5.94%
Cardiovascular-ELECTROPHYSIOLOGY
1.42B
5.91%
Surgery-General
1.38B
5.74%
他の
14.53B
60.56%
地域別USD
会社名
収益
比率
United States
13.71B
57.13%
Europe
5.44B
22.67%
Asia-Pacific, Africa
3.61B
15.06%
Western Hemisphere, excluding U.S.
1.23B
5.13%
事業別
地域別
事業別USD
会社名
収益
比率
Oncology-DARZALEX
3.67B
15.30%
Immunology-STELARA
1.57B
6.54%
Immunology-TREMFYA
1.42B
5.94%
Cardiovascular-ELECTROPHYSIOLOGY
1.42B
5.91%
Surgery-General
1.38B
5.74%
他の
14.53B
60.56%
株主
更新時刻: Mon, Nov 17
更新時刻: Mon, Nov 17
株主統計
種類
株主統計
株主統計
比率
The Vanguard Group, Inc.
10.10%
State Street Investment Management (US)
5.49%
BlackRock Institutional Trust Company, N.A.
5.37%
Geode Capital Management, L.L.C.
2.33%
JP Morgan Asset Management
1.52%
他の
75.18%
株主統計
株主統計
比率
The Vanguard Group, Inc.
10.10%
State Street Investment Management (US)
5.49%
BlackRock Institutional Trust Company, N.A.
5.37%
Geode Capital Management, L.L.C.
2.33%
JP Morgan Asset Management
1.52%
他の
75.18%
種類
株主統計
比率
Investment Advisor
39.87%
Investment Advisor/Hedge Fund
24.21%
Research Firm
3.16%
Pension Fund
2.23%
Bank and Trust
2.07%
Insurance Company
1.61%
Sovereign Wealth Fund
1.41%
Hedge Fund
0.71%
Family Office
0.09%
他の
24.63%
機関投資家保有株
更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
6009
1.82B
75.35%
+8.67M
2025Q3
5885
1.79B
74.44%
+16.50K
2025Q2
5920
1.78B
73.89%
-7.65M
2025Q1
6002
1.80B
74.62%
+4.60M
2024Q4
5953
1.78B
74.14%
+8.28M
2024Q3
5699
1.77B
73.47%
+2.69M
2024Q2
5691
1.75B
72.75%
+9.12M
2024Q1
5685
1.73B
71.58%
-6.08M
2023Q4
5686
1.72B
71.40%
-7.80M
2023Q3
5524
1.72B
71.21%
-159.24M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
The Vanguard Group, Inc.
235.57M
9.78%
-454.61K
-0.19%
Sep 30, 2025
State Street Investment Management (US)
132.21M
5.49%
-591.27K
-0.45%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
129.42M
5.37%
-343.10K
-0.26%
Sep 30, 2025
Geode Capital Management, L.L.C.
56.22M
2.33%
-4.39M
-7.25%
Sep 30, 2025
JP Morgan Asset Management
36.60M
1.52%
-110.36K
-0.30%
Sep 30, 2025
State Farm Insurance Companies
34.11M
1.42%
-262.64K
-0.76%
Sep 30, 2025
Norges Bank Investment Management (NBIM)
31.93M
1.33%
+1.57M
+5.18%
Jun 30, 2025
Wellington Management Company, LLP
25.83M
1.07%
+956.24K
+3.84%
Sep 30, 2025
Morgan Stanley Smith Barney LLC
25.26M
1.05%
-42.23K
-0.17%
Sep 30, 2025
BlackRock Asset Management Ireland Limited
20.93M
0.87%
+1.08M
+5.46%
Sep 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
iShares U.S. Pharmaceuticals ETF
23.7%
VanEck Pharmaceutical ETF
10.06%
FT Vest DJIA Dogs 10 Target Income ETF
9.82%
Health Care Select Sector SPDR Fund
9.32%
Proshares Ultra Health Care
9%
iShares U.S. Healthcare ETF
8.9%
JPMorgan Healthcare Leaders ETF
8.38%
First Trust NASDAQ Pharmaceuticals ETF
8.28%
Fidelity MSCI Health Care Index ETF
7.67%
Franklin Income Focus ETF
7.08%
詳細を見る
iShares U.S. Pharmaceuticals ETF
比率23.7%
VanEck Pharmaceutical ETF
比率10.06%
FT Vest DJIA Dogs 10 Target Income ETF
比率9.82%
Health Care Select Sector SPDR Fund
比率9.32%
Proshares Ultra Health Care
比率9%
iShares U.S. Healthcare ETF
比率8.9%
JPMorgan Healthcare Leaders ETF
比率8.38%
First Trust NASDAQ Pharmaceuticals ETF
比率8.28%
Fidelity MSCI Health Care Index ETF
比率7.67%
Franklin Income Focus ETF
比率7.08%
配当金
過去5年間の配当金総支払額は
46.31B
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
Jan 02, 2026
JNJ.NB Final Cash Dividend of gross USD 1.3 paid on Mar 10, 2026 going ex on Feb 24, 2026
Feb 24, 2026
Mar 10, 2026
Feb 24, 2026
Jan 02, 2025
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Mar 04, 2025 going ex on Feb 18, 2025
Feb 18, 2025
Mar 04, 2025
Feb 18, 2025
Oct 15, 2024
JNJ.NB Final Cash Dividend of gross USD 1.24 paid on Dec 10, 2024 going ex on Nov 26, 2024
Nov 26, 2024
Dec 10, 2024
Nov 26, 2024
Jul 17, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Sep 10, 2024 going ex on Aug 27, 2024
Aug 27, 2024
Sep 10, 2024
Aug 27, 2024
Apr 16, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Jun 04, 2024 going ex on May 20, 2024
May 21, 2024
Jun 04, 2024
May 20, 2024
Jan 02, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Mar 05, 2024 going ex on Feb 16, 2024
Feb 20, 2024
Mar 05, 2024
Feb 16, 2024
Oct 19, 2023
JNJ.NB Final Cash Dividend of gross USD 1.19 paid on Dec 05, 2023 going ex on Nov 20, 2023
Nov 21, 2023
Dec 05, 2023
Nov 20, 2023
Jul 20, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Sep 07, 2023 going ex on Aug 25, 2023
Aug 28, 2023
Sep 07, 2023
Aug 25, 2023
Apr 18, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Jun 06, 2023 going ex on May 22, 2023
May 23, 2023
Jun 06, 2023
May 22, 2023
Jan 03, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.13 paid on Mar 07, 2023 going ex on Feb 17, 2023
Feb 21, 2023
Mar 07, 2023
Feb 17, 2023
詳細を見る
株式分割
日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
